Life Extension launched new nutritional supplement known as NAD+ Cell Regenerator™ in which the main ingredient used is NIAGEN™ supplied by Chromadex Corp (OTCMKTS:CDXC). The product is introduced as a new anti-aging supplement that will also boost vitality in the body. Chromadex is known for supplying the proprietary ingredients and solutions to the various industries including animal health, cosmetics, pharmaceuticals, dietary supplements and food and beverage.
NIAGEN™ is the patent protected product of Chromadex Corp (OTCMKTS:CDXC) and is the first commercial available form of nicotinamide riboside. It is the leading ingredient in NAD+ Cell Regenerator™ as it has the capability to enhance levels of NAD+ in tissue and cells. The regenerator therapy is based on a simple fact that higher the levels of NAD+, healthier aging a person experiences in its lifetime. The ingredient activates Sirtuin function and also stimulates mitochondrial energy production.
The management view
Paul Gilner, the CEO of Life Extension, said that the company offers scientifically proven supplements for overall wellness. It is a moment of proud as it introduces NIAGEN™ nicotinamide riboside which results in health aging. It is significant in today’s world where stress, hectic life schedule and unhealthy eating habits are deteriorating the health of people. In such a scenario, the product can target a large number of people in the country. The product will enhance the vitality, will improve metabolic health and make the defense system stronger against premature aging.
The growing industry
Frank Jaksch, the CEO of Chromadex Corp (OTCMKTS:CDXC), said that Life extension is known for its high quality, innovative and highly efficacious dietary supplements. ChromaDex is delighted to be associated with Life Extension by featuring their branded nicotinamide riboside in NAD+ Cell Regenerator™. The health aging and other health supplements market is seeing a growth, and the launch of NAD+ Cell Regenerator™ will open new doors of success and strong financial performance for both the companies.